Skip to main content

Table 1 Baseline characteristics of 27 patients with relapsed or refractory multiple myeloma (RRMM)

From: Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

Characteristic No. of patients (%)
Agea (years) 56 (36–77)
Sex
 Men 18 (66.7)
 Women 9 (33.3)
ISS stageb
 I 6 (23.1)
 II 14 (53.8)
 III 6 (23.1)
Time since diagnosisa (months) 21 (4–60)
Subtype of disease
 IgG 11 (40.7)
 IgA 6 (22.2)
 IgD 5 (18.5)
 Light chain 5 (18.5)
β2-microglobulinb
 Levela (mg/L) 3.4 (1.1–16.7)
 <3.5 mg/L 14 (53.8)
 ≥3.5 mg/L 12 (46.2)
Prior therapy
 Numbera (cycles) 3 (1–8)
 0–3 cycles 14 (51.9)
 >3 cycles 13 (48.1)
Prior regimen
 Glucocorticoids 25 (92.6)
 Alkylating agents 23 (85.2)
 IMiDs (thalidomide or lenalidomide) 21 (77.8)
 Vincristine 19 (70.3)
 Bortezomib 14 (51.9)
 Both bortezomib and IMiDs 9 (33.3)
 Autologous stem cell transplantation 5 (18.5)
  1. ISS international staging system, IMiDs immunomodulatory drugs
  2. aThese values are presented as median followed by ranges in the parentheses; other values are presented as number of patients followed by percentages in the parentheses
  3. bBaseline β2-microglobulin was not determined in one patient; who could not be grouped into any ISS stage